AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer

Loading news article.

AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer | WAPE

AstraZeneca Says Phase 3 DeLLphi-305 Interim Analysis Showed IMFINZI Plus Amgen's Tarlatamab Met Primary Endpoint With Statistically Significant Overall Survival Improvement vs. IMFINZI Alone In Extensive-Stage Small Cell Lung Cancer

Article summary

Related companies

Comments —